208 related articles for article (PubMed ID: 27647003)
1. Rapid Virological Response After Early Treatment with a Combined Therapy of Ledipasvir and Sofosbuvir in HCV Genotype 4 After Living Donor Liver Transplantation in a HCC Downstaged Patient: Case Report and Review of the Literature.
Obed A; Bashir A; Jarrad A
Am J Case Rep; 2016 Sep; 17():672-5. PubMed ID: 27647003
[TBL] [Abstract][Full Text] [Related]
2. Treatment with sofosbuvir and ledipasvir without ribavirin for 12 weeks is highly effective for recurrent hepatitis C virus genotype 1b infection after living donor liver transplantation: a Japanese multicenter experience.
Ueda Y; Ikegami T; Akamatsu N; Soyama A; Shinoda M; Goto R; Okajima H; Yoshizumi T; Taketomi A; Kitagawa Y; Eguchi S; Kokudo N; Uemoto S; Maehara Y
J Gastroenterol; 2017 Aug; 52(8):986-991. PubMed ID: 28138756
[TBL] [Abstract][Full Text] [Related]
3. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
[TBL] [Abstract][Full Text] [Related]
4. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.
Manns M; Samuel D; Gane EJ; Mutimer D; McCaughan G; Buti M; Prieto M; Calleja JL; Peck-Radosavljevic M; Müllhaupt B; Agarwal K; Angus P; Yoshida EM; Colombo M; Rizzetto M; Dvory-Sobol H; Denning J; Arterburn S; Pang PS; Brainard D; McHutchison JG; Dufour JF; Van Vlierberghe H; van Hoek B; Forns X;
Lancet Infect Dis; 2016 Jun; 16(6):685-697. PubMed ID: 26907736
[TBL] [Abstract][Full Text] [Related]
5. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?
Jain A; Miller D; Schreibman I; Riley TR; Krok KL; Dohi T; Sharma R; Kadry Z
Hepatol Int; 2019 Mar; 13(2):190-198. PubMed ID: 30680672
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation.
Beinhardt S; Al-Zoairy R; Kozbial K; Stättermayer AF; Maieron A; Stauber R; Strasser M; Zoller H; Graziadei I; Rasoul-Rockenschaub S; Trauner M; Ferenci P; Hofer H
Liver Int; 2018 Jul; 38(7):1188-1197. PubMed ID: 29197145
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
[TBL] [Abstract][Full Text] [Related]
9. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
[TBL] [Abstract][Full Text] [Related]
10. Case report: 8 years after liver transplantation: de novo hepatocellular carcinoma 8 months after HCV clearance through IFN-free antiviral therapy.
Ramadori G; Bosio P; Moriconi F; Malik IA
BMC Cancer; 2018 Mar; 18(1):257. PubMed ID: 29510685
[TBL] [Abstract][Full Text] [Related]
11. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
[TBL] [Abstract][Full Text] [Related]
12. Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Jung J; Kwon JH; Song GW; Tak EY; Kirchner VA; Lee SG
J Gastrointest Surg; 2018 Aug; 22(8):1334-1342. PubMed ID: 29679347
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Lau G; Benhamou Y; Chen G; Li J; Shao Q; Ji D; Li F; Li B; Liu J; Hou J; Sun J; Wang C; Chen J; Wu V; Wong A; Wong CL; Tsang ST; Wang Y; Bassit L; Tao S; Jiang Y; Hsiao HM; Ke R; Perelson AS; Schinazi RF
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):97-104. PubMed ID: 27917405
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature.
Fabbri G; Mastrorosa I; Vergori A; Mazzotta V; Pinnetti C; Grisetti S; Zaccarelli M; Ammassari A; Antinori A
BMC Infect Dis; 2017 Mar; 17(1):182. PubMed ID: 28249574
[TBL] [Abstract][Full Text] [Related]
15. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study.
Abergel A; Asselah T; Metivier S; Kersey K; Jiang D; Mo H; Pang PS; Samuel D; Loustaud-Ratti V
Lancet Infect Dis; 2016 Apr; 16(4):459-64. PubMed ID: 26803446
[TBL] [Abstract][Full Text] [Related]
16. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan.
Akuta N; Sezaki H; Suzuki F; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Med Virol; 2017 Feb; 89(2):284-290. PubMed ID: 27357737
[TBL] [Abstract][Full Text] [Related]
17. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
[TBL] [Abstract][Full Text] [Related]
18. Use of a hepatitis C virus (HCV) RNA-positive donor in a treated HCV RNA-negative liver transplant recipient.
Campos-Varela I; Agudelo EZ; Sarkar M; Roberts JP; Terrault NA
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29125670
[TBL] [Abstract][Full Text] [Related]
19. Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: A real-life observational study.
Zeng QL; Xu GH; Zhang JY; Li W; Zhang DW; Li ZQ; Liang HX; Li CX; Yu ZJ
J Hepatol; 2017 Jun; 66(6):1123-1129. PubMed ID: 28189754
[TBL] [Abstract][Full Text] [Related]
20. Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation.
Oya Y; Sugawara Y; Watanabe T; Yoshimaru Y; Honda M; Hashimoto S; Yoshii D; Isono K; Hayashida S; Yamamoto H; Tanaka M; Sasaki Y; Inomata Y
Biosci Trends; 2017 Jan; 10(6):496-499. PubMed ID: 27990005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
